PMHS · Polomar Health Services, Inc.
$0.12
At close · Oct 19
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management evaluated all relevant conditions and events that are reasonably known or reasonably knowable, in the aggregate, as of the date the financial statements are issued and determined that substantial doubt exists about the Company's ability to continue as a going concern. The Company's ability to continue as a going concern is dependent on the Company's ability to generate revenues and raise capital. The Company has not generated sufficient income and has historically depended on notes or equity to fund operations. As of June 30, 2026, the Company has an accumulated deficit of $13,526,169. These factors raise substantial doubt about the Company's ability to continue as a going concern for one year from the date of filing of the 10-Q.”View the 10-Q filed Aug 14, 2026
Market Cap
$3.55M
Shares
28.38M
Volume · Oct 19
15K
Avg daily vol (3M)
15.9K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.12
Open$0.10
Day$0.10–0.12
Available close range$0.07–0.80
Avg vol 30d17K
Short int940 · 0.0% float · 1.0d
Short vol81%
DataJan 2020–Oct 2026
Filing10-Q · Aug 14
The closing range uses available history since Nov 14, 2025; less than a full year is stored.
Up next
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$3.17M
Trailing 12 months
Net income (TTM)
−$9.46M
Trailing 12 months
Revenue growth YoY
+27,847.1%
Year over year
Operating margin
-295.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.4%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
—
Latest settlement
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−92%
below
Price vs 50-day avg
−29%
below
RSI (14)
46
neutral
MACD trend
Negative
52-week position
7%
near low
Momentum
relative strength
1-month return
−40%
trailing
6-month return
−91%
trailing
YTD return
−85%
this year
Relative strength
−98%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $2 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.00% of float · ▼ -81.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Fundamentals
Revenue growth
+1002%
Y/Y
Gross margin
71%
expanding
EPS growth
−680%
Y/Y
Free cash flow
$-486.9K
Quant / Vol
risk profile
Volatility
1102%
annualized · 1-yr
Max drawdown
−100%
past year
ATR
44.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−92%
Bearish
Price vs 50-day avg
−29%
Bearish
RSI (14)
46
Neutral
MACD trend
Negative
Bearish
52-week position
7%
Bearish
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50d $0 › 200d $2 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.00% of float · ▼ -81.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its available closing range
Range low $0
Now $0 · 7%
Range high $1
vs 200-day avg -92%
vs 50-day avg -29%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Gross margin | 61.2% | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Pharmaceutical Retailers — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PMHS
this stock
Polomar Health Services, Inc.
|
$3.55M | -85.0% | +1002.0% | — | 0.0% |
|
RTEZ
REST EZ Inc.
|
$4.20B | — | -100.0% | — | 0.0% |
|
HITI
High Tide Inc.
|
$233.55M | -1.1% | — | — | 0.8% |
|
BHIC
BioScience Health Innovations, Inc.
|
$79.68M | — | +208.3% | — | 0.0% |
|
SHFH
Scientist Home Future Health Ltd
|
$40.32M | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Financials
Filings
SEC Filings
Latest
8-K
- Filed
- Oct 19, 2026
- This year
- 13
Polomar Health Services, Inc. announced the resignations of directors Alexandra Peterson and Gabrielle Toledano on October 15, 2026, effective October 14, 2026, with the Board reduced from five to three directors.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PMHS | -20.0% | -40.0% | -90.8% | -29.4% | -85.0% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | -18.5% | -39.1% | -98.5% | -29.9% | -97.4% |